Related Experiment Video
Updated: May 30, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
[Treatment of lupus nephritis]
Lucía Silva Fernández1, José Luis Andréu Sánchez, Ellen M Ginzler
1Servicio de Reumatología. Complexo Hospitalario de Pontevedra. Pontevedra. España.
Abstract:
Lupus nephritis is a relevant source of morbidity and mortality in patients with systemic lupus erythematosus. The standard therapy of remission induction in severe lupus nephritis is based on the use of monthly intravenous cyclophosphamide. Recent data have established that the maintenance of remission in lupus nephritis can be achieved with azathioprine or mycophenolate mofetil, with less adverse effects than quarterly intravenous cyclophosphamide. In recent years, a number of controlled randomized clinical trials have been published, opening new therapeutic options in the induction of remission in lupus nephritis, such as less aggressive regimens of intravenous cyclophosphamide or mycophenolate mofetil. Further studies are needed for establishing the optimal therapy of lupus nephritis patients.
More Related Videos
Related Concept Videos
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Kidney Disease III: Interprofessional Care
Kidney Transplant II: Surgical Procedure
Acute Pyelonephritis II: Diagnostic Studies and Management
Kidney Transplant III: Nursing Management
